Regional Stereotactic Radiosurgery: Bridging the Cancer Care Gap for Rural Patients

Is Local SRS Bridging the Gap in Regional Cancer Care?

Implementing intracranial stereotactic radiosurgery (SRS) services in regional hospitals represents a significant advancement in addressing healthcare disparities for cancer patients with brain metastases. A recent prospective study conducted at a North Queensland regional hospital provides compelling evidence for both the clinical efficacy and cost-effectiveness of this approach. Between September 2022 and December 2024, 34 patients with limited intracranial metastatic disease received SRS treatment locally rather than traveling to distant metropolitan centers. The patient cohort had a median age of 65 years, with non-small cell lung cancer being the predominant primary malignancy (42%). The regional service primarily treated solitary brain metastases, with careful patient selection ensuring appropriate cases were managed locally while more complex presentations continued to be referred to metropolitan centers. Treatment planning utilized the Monaco system with delivery on an Elekta Versa HD™ linear accelerator, maintaining the technical standards expected in specialized cancer centers. The most common treatment regimen was 24 Gy delivered in three fractions, administered to 71% of patients, aligning with contemporary evidence-based protocols for brain metastases management.

Do Cost Savings Justify Local Treatment?

The cost analysis revealed meaningful differences between regional and metropolitan treatment scenarios. While medical costs remained equivalent between the two settings, non-medical expenses—including travel, accommodation, and informal caregiving costs—were substantially reduced with local treatment delivery. The mean total cost per patient was AUD 7450 (95% CI 6657–8254) for metropolitan treatment versus AUD 6690 (95% CI 6005–7375) at the regional hospital. This represents a significant saving that directly benefits patients, families, and healthcare systems. For many rural patients, these non-medical costs can present substantial barriers to accessing specialized care, potentially leading to treatment delays or decisions to forego optimal therapy altogether. In regions like Queensland, where the Patient Travel Subsidy Scheme often covers these expenses, reducing such costs through local service provision allows the reallocation of resources to support other patients requiring specialized care that remains unavailable locally. This financial analysis underscores the economic viability of expanding specialized radiotherapy services to regional centers, particularly for treatments like SRS that can be delivered in relatively few fractions.

Can Regional SRS Match Metropolitan Outcomes?

Crucially, the clinical outcomes observed in this regional cohort were comparable to those reported in established metropolitan centers. The median survival time following radiotherapy was 15.7 months (95% CI: 7.8–23.6), which compares favorably with published Canadian and Australian metropolitan series reporting median survival durations of 9.6 and 11.8 months, respectively. Radiation necrosis, a significant potential complication of SRS, occurred in 24% of patients—slightly higher than the 13.2-15.6% reported in metropolitan series, though this difference may reflect the small sample size rather than a meaningful clinical distinction. Progressive intracranial disease developed in 56% of patients during follow-up, consistent with expected patterns of disease behavior following SRS for brain metastases. These outcomes suggest that with appropriate patient selection, adequate training, and robust quality assurance processes, regional centers can safely deliver intracranial SRS with efficacy comparable to established high-volume metropolitan services. This finding challenges the conventional wisdom that specialized radiotherapy services must remain centralized to maintain quality and safety standards.

What Impact Does Local Treatment Have on Rural Health Equity?

The implementation of regional SRS services addresses several well-documented challenges faced by rural and regional cancer patients. Evidence consistently shows that patients from rural communities experience longer wait times for specialist care, including cancer treatment, and generally have poorer health outcomes compared to metropolitan populations. These disparities are particularly pronounced for Aboriginal and Torres Strait Islander peoples, who face additional cultural and linguistic barriers when accessing care far from their communities. By bringing specialized radiotherapy services closer to where patients live, regional SRS programs can potentially improve treatment uptake, reduce delays in care initiation, enhance continuity of care, and allow patients to maintain vital family and community support networks during treatment. For Aboriginal and Torres Strait Islander patients specifically, receiving treatment closer to Country can significantly reduce the psychosocial burden associated with traveling to distant metropolitan centers and enable more culturally appropriate care delivery. Future research incorporating patient-reported outcomes would be valuable to quantify these psychosocial benefits of local treatment delivery.

How Can Regional Centers Sustain High-Quality SRS?

Establishing specialized services in regional centers is not without challenges, particularly concerns about maintaining adequate patient volumes to ensure clinical proficiency and cost-effectiveness. The traditional argument for centralization of complex services has been that higher patient volumes lead to better outcomes, improved resource utilization, and reduced per-patient costs. However, this study demonstrates that through careful implementation planning and strong partnerships with metropolitan centers, it is possible to develop local expertise while maintaining both clinical quality and cost efficiency. The researchers highlight several strategies to mitigate concerns about lower patient volumes in regional settings, including formalized hub-and-spoke service models that facilitate knowledge sharing between metropolitan and regional centers, regular staff training programs, universally adopted clinical practice guidelines, cross-institutional quality assurance processes, and the use of telehealth technologies for remote consultation and support. These collaborative approaches enable regional centers to benefit from the experience and expertise of high-volume metropolitan institutions while building local capacity to deliver specialized care.

Could Collaborative Models Enhance Regional SRS Services?

The North Queensland SRS program exemplifies this collaborative approach, with careful patient assessment determining whether treatment can be safely provided locally or whether referral to a metropolitan center is more appropriate based on both clinical and non-clinical factors. This patient-centered decision-making process ensures that the benefits of local treatment are balanced against the need for specialized expertise in complex cases. The program's close collaboration with metropolitan institutions also facilitates ongoing quality improvement and professional development. As regional services mature and local expertise grows, the range of patients who can be safely treated locally may expand, potentially including those with multiple lesions or metastases in more challenging anatomical locations. This gradual expansion of capability, guided by rigorous outcome monitoring and benchmarking against metropolitan standards, represents a responsible approach to building regional capacity while maintaining high-quality care.

What Study Limitations Should We Consider?

The study acknowledges several limitations, including its relatively small sample size and the fact that only patients with solitary lesions not located in eloquent brain areas were treated locally. The cost comparison was based on a counterfactual scenario rather than direct observation of two patient cohorts. Additionally, the analysis did not capture patient-reported outcomes that might better quantify the psychosocial benefits of receiving treatment closer to home. Despite these limitations, the findings provide compelling preliminary evidence supporting the feasibility, safety, and cost-effectiveness of regional SRS services. As the program continues and more patients are treated, longer-term follow-up and larger cohort analyses will enable more robust comparisons with metropolitan outcomes and further refinement of patient selection criteria. The authors also highlight emerging evidence supporting preoperative SRS over postoperative approaches for brain metastases, noting that adopting such protocols would require additional resources and multidisciplinary capabilities that may be challenging to establish in regional settings with existing capacity constraints.

Could This Model Transform Future Regional Cancer Care?

The successful implementation of regional intracranial SRS services raises important questions about the future of specialized cancer care delivery in rural and remote settings. Could this model be extended to other complex cancer treatments traditionally confined to metropolitan centers? How might healthcare policies and funding models be restructured to better support the establishment of specialized services in regional areas? What additional quality assurance mechanisms might be necessary to ensure that outcomes remain comparable between regional and metropolitan centers as programs expand? How can we better quantify the non-medical benefits of local treatment delivery, particularly for Indigenous patients and those from culturally and linguistically diverse backgrounds? Addressing these questions will require ongoing collaboration between clinicians, researchers, policymakers, and patient advocates to develop sustainable models of specialized cancer care that reduce geographical disparities while maintaining high-quality outcomes. The North Queensland experience provides a valuable blueprint for how such services can be successfully implemented, potentially transforming access to advanced cancer care for rural and regional populations across Australia and similar geographically dispersed healthcare systems worldwide.

Summary

A prospective study conducted at a North Queensland regional hospital demonstrates that implementing intracranial stereotactic radiosurgery (SRS) services locally for cancer patients with brain metastases is both clinically effective and cost-efficient. Between September 2022 and December 2024, 34 patients received SRS treatment locally rather than traveling to metropolitan centers, with the majority having non-small cell lung cancer as their primary malignancy. The regional service achieved clinical outcomes comparable to established metropolitan centers, with a median survival of 15.7 months following radiotherapy. Cost analysis revealed significant savings, with mean total costs per patient of AUD 6690 for regional treatment versus AUD 7450 for metropolitan treatment, primarily due to reduced travel, accommodation, and caregiving expenses. The radiation necrosis rate was 24%, slightly higher than metropolitan series but within acceptable ranges for the sample size. The program utilized careful patient selection, treating primarily solitary brain metastases while referring more complex cases to metropolitan centers. Implementation strategies included formalized hub-and-spoke service models, regular staff training, standardized clinical guidelines, cross-institutional quality assurance, and telehealth support. The study highlights how regional SRS services can address healthcare disparities faced by rural patients, particularly Aboriginal and Torres Strait Islander peoples, by reducing barriers to accessing specialized care and enabling treatment closer to home and community support networks. Despite limitations including small sample size and lack of patient-reported outcome measures, the findings provide compelling evidence that with appropriate planning, training, and collaboration with metropolitan centers, regional hospitals can safely deliver specialized radiotherapy services while maintaining quality standards and improving healthcare equity for geographically dispersed populations.